← All stocks

Xilio Therapeutics, Inc.

XLO Net buying
CIK 0001840233 #4621 in the set updated 21 Sep 2026
Bought (12 mo)
$43.95K
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$5.70K
$5.70K on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 2 sales
Net
+$38.25K
+$43.95K against sales at will

By person

6 insiders · 3 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Shannon James Samuel
Director
$43.95K (1)
+$43.95K
10,000
$87.90K
Frankenfield Christopher James
Chief Financial Officer
$4.52K (1) scheduled
−$4.52K
24,766
$217.69K
Brennan Kevin M.
SVP, FINANCE AND ACCOUNTING
$1.17K (1) scheduled
−$1.17K
6,371
$56.00K
GILEAD SCIENCES, INC. entity
10% owner
9,105,451
$80.04M
+24.0%
Russo Rene
PRESIDENT AND CEO
325,422
$2.86M
+62.2%
Luptakova Katarina
CHIEF MEDICAL OFFICER
33,250
$292.27K

No percentages here. This company's share count has moved by a factor of 9.1 over the window, from 5,782,511 to 52,500,328 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Frankenfield Christopher James
2 Jan 2026
Chief Financial Officer
Sold on a plan
7,030
$0.64
$4.52K
Brennan Kevin M.
2 Jan 2026
SVP, FINANCE AND ACCOUNTING
Sold on a plan
1,826
$0.64
$1.17K

What was left out

Form 4 filings counted 19
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 85,250
History held since 25 Oct 2021